<progress id="397nd"></progress>

<progress id="397nd"></progress>

<progress id="397nd"><meter id="397nd"><mark id="397nd"></mark></meter></progress><progress id="397nd"><meter id="397nd"><mark id="397nd"></mark></meter></progress>

<big id="397nd"></big>

<noframes id="397nd"><em id="397nd"><strike id="397nd"></strike></em>

<progress id="397nd"></progress>

<big id="397nd"><meter id="397nd"></meter></big>

<big id="397nd"><progress id="397nd"><mark id="397nd"></mark></progress></big>

<big id="397nd"></big>

<progress id="397nd"></progress>

<big id="397nd"></big>

<big id="397nd"><progress id="397nd"><meter id="397nd"></meter></progress></big>

<meter id="397nd"></meter>

<big id="397nd"><meter id="397nd"></meter></big><big id="397nd"></big><big id="397nd"></big><progress id="397nd"><meter id="397nd"><mark id="397nd"></mark></meter></progress>

<progress id="397nd"></progress><progress id="397nd"><meter id="397nd"><mark id="397nd"></mark></meter></progress>

<progress id="397nd"></progress>

<progress id="397nd"></progress><meter id="397nd"></meter>

<progress id="397nd"></progress>

<big id="397nd"><progress id="397nd"></progress></big>

<big id="397nd"></big><progress id="397nd"></progress><progress id="397nd"><meter id="397nd"><menuitem id="397nd"></menuitem></meter></progress>

<big id="397nd"></big>

<progress id="397nd"><menuitem id="397nd"><mark id="397nd"></mark></menuitem></progress>

<meter id="397nd"></meter>

<progress id="397nd"><menuitem id="397nd"></menuitem></progress>

<progress id="397nd"><meter id="397nd"></meter></progress>

<big id="397nd"></big>

<big id="397nd"><meter id="397nd"></meter></big>

<progress id="397nd"></progress>

<progress id="397nd"><menuitem id="397nd"><ins id="397nd"></ins></menuitem></progress><big id="397nd"></big><meter id="397nd"></meter><meter id="397nd"><menuitem id="397nd"><ins id="397nd"></ins></menuitem></meter>

至美 OriMIRACLETM S
開啟實體瘤全程管理新時代

實體瘤中,微小殘留病灶(MRD)也稱為分子殘留病灶,指的是經過治療后,傳統影像學(包括PET/CT)或實驗室方法不能發現,但通過液體活檢發現的癌來源分子異常,是腫瘤復發的直接原因,代表著腫瘤的持續存在和臨床進展的可能
MRD檢測在評估治療效果提供預后信息方面有很重要的作用
至美 OriMIRACLETMS是一款基于ctDNA指導、專為實體瘤MRD監測設計的全程管理產品。依據患者全外顯子(WES+)基因突變圖譜個體化定制MRD Panel(MRD),適用于泛實體瘤,可用于根治性治療患者的復發風險分層和動態復發監測

產品優勢

· 符合MRD臨床應用共識的檢測技術要求

· 個體化定制,持續監測

· 超高樣本靈敏性和樣本特異性

18禁无遮挡羞羞污污污污网站